M J Burke

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. pmc Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia
    Michael J Burke
    Division of Pediatric Hematology Oncology, University of Minnesota Amplatz Children s Hospital, Minneapolis, MN, USA
    Biol Blood Marrow Transplant 19:1021-5. 2013
  2. pmc Survival differences between adolescents/young adults and children with B precursor acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation
    Michael J Burke
    Division of Pediatric Hematology Oncology, University of Minnesota, Amplatz Children s Hospital, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 19:138-42. 2013
  3. doi request reprint Treatment of relapsed acute lymphoblastic leukemia: approaches used by pediatric oncologists and bone marrow transplant physicians
    Michael J Burke
    Division of Pediatric Hematology Oncology, University of Minnesota, Minneapolis, MN, USA
    Pediatr Blood Cancer 58:840-5. 2012
  4. doi request reprint Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival
    M J Burke
    Division of Hematology Oncology Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 43:107-13. 2009
  5. doi request reprint Treatment of a CNS relapse while on therapy for Burkitt lymphoma
    Michael J Burke
    Division of Pediatric Hematology Oncology Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota, USA
    Pediatr Blood Cancer 52:290-2. 2009
  6. doi request reprint Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients
    M J Burke
    University of Minnesota, Minneapolis, 55455, USA
    Bone Marrow Transplant 44:169-74. 2009
  7. doi request reprint The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era
    Michael J Burke
    Division of Pediatric Hematology Oncology Blood and Marrow Transplantation, University of Minnesota Children s Hospital Fairview, Minneapolis, Minnesota 55455, USA
    Pediatr Blood Cancer 53:992-5. 2009
  8. doi request reprint Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL)
    Michael J Burke
    Division of Pediatric Hematology Oncology Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Pediatr Blood Cancer 53:1289-94. 2009
  9. doi request reprint Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse
    J C Beck
    Division of Pediatric Hematology Oncology Bone and Marrow Transplantation, University of Minnesota, Minneapolis, MN 55455 USA
    Bone Marrow Transplant 46:950-5. 2011
  10. pmc Lower leukemia relapse in pediatric patients with pulmonary cytolytic thrombi following allogeneic transplant
    A R Smith
    Pediatric Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 46:368-71. 2011

Detail Information

Publications11

  1. pmc Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia
    Michael J Burke
    Division of Pediatric Hematology Oncology, University of Minnesota Amplatz Children s Hospital, Minneapolis, MN, USA
    Biol Blood Marrow Transplant 19:1021-5. 2013
    ..62), relapse (11% versus 7%, P = .71), or treatment-related mortality (17% versus 14%, P = .89). Children and young adults with HR-AML have comparable outcomes to standard-risk patients following allo-HCT in CR1...
  2. pmc Survival differences between adolescents/young adults and children with B precursor acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation
    Michael J Burke
    Division of Pediatric Hematology Oncology, University of Minnesota, Amplatz Children s Hospital, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 19:138-42. 2013
    ..Further improvements in peritransplantation care are needed to limit complications in AYA patients...
  3. doi request reprint Treatment of relapsed acute lymphoblastic leukemia: approaches used by pediatric oncologists and bone marrow transplant physicians
    Michael J Burke
    Division of Pediatric Hematology Oncology, University of Minnesota, Minneapolis, MN, USA
    Pediatr Blood Cancer 58:840-5. 2012
    ..Management of relapsed B-precursor acute lymphoblastic leukemia (ALL) is challenging and varied. We hypothesized that treatment approaches differ between pediatric oncologists and bone marrow transplant (BMT) physicians...
  4. doi request reprint Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival
    M J Burke
    Division of Hematology Oncology Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 43:107-13. 2009
    ..We suggest that imatinib be included in the peri-transplant management of all patients with Ph+ ALL...
  5. doi request reprint Treatment of a CNS relapse while on therapy for Burkitt lymphoma
    Michael J Burke
    Division of Pediatric Hematology Oncology Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota, USA
    Pediatr Blood Cancer 52:290-2. 2009
    ..Our experience shows both the feasibility and efficacy of such an approach in a patient with an otherwise very poor prognosis...
  6. doi request reprint Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients
    M J Burke
    University of Minnesota, Minneapolis, 55455, USA
    Bone Marrow Transplant 44:169-74. 2009
    ..44). Thus, patients treated with imatinib either before or after myeloablative allo-HCT had no increase in cardiac toxicity...
  7. doi request reprint The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era
    Michael J Burke
    Division of Pediatric Hematology Oncology Blood and Marrow Transplantation, University of Minnesota Children s Hospital Fairview, Minneapolis, Minnesota 55455, USA
    Pediatr Blood Cancer 53:992-5. 2009
    ..As the treatment of Philadelphia positive (Ph+) leukemias in the era of imatinib continues to evolve, the role of allogeneic hematopoietic cell transplantation (allogeneic-HCT) in first remission is becoming more unclear...
  8. doi request reprint Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL)
    Michael J Burke
    Division of Pediatric Hematology Oncology Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Pediatr Blood Cancer 53:1289-94. 2009
    ..Since the introduction of imatinib into the treatment of this disease, the role of allogeneic HCT is more uncertain...
  9. doi request reprint Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse
    J C Beck
    Division of Pediatric Hematology Oncology Bone and Marrow Transplantation, University of Minnesota, Minneapolis, MN 55455 USA
    Bone Marrow Transplant 46:950-5. 2011
    ..04). These results suggest that allo-HCT should be pursued in children after a first marrow relapse, rather than waiting for subsequent recurrence...
  10. pmc Lower leukemia relapse in pediatric patients with pulmonary cytolytic thrombi following allogeneic transplant
    A R Smith
    Pediatric Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 46:368-71. 2011
    ..02), cGVHD (P=0.01) and development of PCT (P<0.01) were independently associated with less relapse. These data suggest that patients with PCT are at greater risk for GVHD, but at lower risk of leukemia relapse...
  11. doi request reprint A clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD)
    N Gossai
    Department of Pediatrics, University of Minnesota Amplatz Children s Hospital, Minneapolis, MN, USA
    Bone Marrow Transplant 49:440-2. 2014
    ..5%) and two from transplant-related mortality (25%). The combination of reduced-dose clofarabine, CY and etoposide as bridging therapy appears to be well tolerated in patients with relapsed ALL and is effective in reducing pre-HCT MRD. ..